세계의 편두통 시장 : 유형별, 치료 유형별, 약제 클래스별, 지역별(-2032년)

Global Migraine Market Research Report Information by Type (Episodic and Chronic), By Treatment Type (Preventive, Abortive), By Drug Class (Triptans, Ergots, and Others), And by Region (North America, Europe, Asia-Pacific, And Rest of The World) Market Forecast Till 2032

Overview of the Market

In 2023, the migraine market was estimated to be worth USD 5.68 billion. The global migraine market is expected to expand at a compound annual growth rate (CAGR) of 3.83% from 2024 to 2032, from USD 6.00 billion in 2024 to USD 8.42 billion.

The two main factors propelling market expansion are the rise in migraine issues worldwide and the growing public knowledge of new medication classes.

Growing public awareness of new drug classes and a rise in migraine problems globally are two factors influencing the target market's growth. It is also anticipated that the introduction of calcitonin gene-related peptide (CGRP) will facilitate the growth of this enterprise. Migraine is a recurrent, severe headache that is accompanied by photophobia, phonophobia, and nausea. Genes play a role in the development of illness. Out-of-balance emotions, including dejection, tension, anxiety, shock, and excitement, can cause migraine headaches. Each migraine attack varies in length and intensity and often affects one side of the head. Factors include an increase in migraine frequency with substantial unmet needs, rising R&D expenditures resulting in a sizable drug pipeline, and an increase in our understanding of migraine and available treatments.

Perspectives on Market Segments

The migraine market is divided into two divisions based on type: episodic and chronic.

The migraine market is divided into two segments based on the kind of treatment: preventive and abortive.

Surgery has divided the market data into three categories: triptans, ergots, and others.

Regional Perspectives on Migraines

The analysis offers market insights by region, including Asia-Pacific, Europe, North America, and the rest of the world. Throughout the study period, a notable compound annual growth rate (CAGR) is anticipated in the Asia Pacific migraine market. As healthcare expenses rise and infrastructure in emerging countries like China and India improves, the Asia Pacific acute migraine treatment market is predicted to grow in size. The easy availability of reasonably priced migraine treatment choices backed by growing regulatory body initiatives is another significant aspect that is probably propelling the regional market. by the Brand Equity Foundation of India.

The second largest market share is held by the migraine industry in Europe. Two reasons driving the target market's growth are the rise in migraine issues worldwide and the growing public knowledge of new medicine classes. Furthermore, the launch of calcitonin gene-related peptide (CGRP) is expected to support the growth of this sector.

From 2024 to 2032, the North American migraine market is anticipated to expand at the quickest compound annual growth rate. increasing financial contributions from powerful U.S.-based parties. The local market is expected to gain from the substantial research and development activities conducted in the US, Canada, and other nations to identify novel treatment choices. According to the American Family Physician, there are approximately 441.5 million adults in the United States, of whom 6-9% are men and 18-26% are women. In 2009, the United States suffered a migraine.

Key Players

Among the leading companies in the migraine market are Johnson & Johnson, Endo International Plc, GlaxoSmithKline Plc, Abbott Laboratories, Teva Pharmaceutical Industries Limited, Allergan Plc, Pfizer Inc., AstraZeneca, and Impax Laboratories.

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

2 MARKET INTRODUCTION

• 2.1 DEFINITION
• 2.2 SCOPE OF THE STUDY
• 2.3 RESEARCH OBJECTIVE
• 2.4 MARKET STRUCTURE

3 RESEARCH METHODOLOGY

• 3.1 OVERVIEW
• 3.2 DATA FLOW
  • 3.2.1 DATA MINING PROCESS
• 3.3 PURCHASED DATABASE:
• 3.4 SECONDARY SOURCES:
  • 3.4.1 SECONDARY RESEARCH DATA FLOW:
• 3.5 PRIMARY RESEARCH:
  • 3.5.1 PRIMARY RESEARCH DATA FLOW:
  • 3.5.2 PRIMARY RESEARCH: NUMBER OF INTERVIEWS CONDUCTED
  • 3.5.3 PRIMARY RESEARCH: REGIONAL COVERAGE
• 3.6 APPROACHES FOR MARKET SIZE ESTIMATION:
  • 3.6.1 REVENUE ANALYSIS APPROACH
• 3.7 DATA FORECASTING
  • 3.7.1 DATA FORECASTING TECHNIQUE
• 3.8 DATA MODELING
  • 3.8.1 MICROECONOMIC FACTOR ANALYSIS:
  • 3.8.2 DATA MODELING:
• 3.9 TEAMS AND ANALYST CONTRIBUTION

4 MARKET DYNAMICS

• 4.1 DRIVERS
  • 4.1.1 INCREASING INCIDENCES/PREVALENCE OF MIGRAINE
  • 4.1.2 RISING APPROVAL FOR THERAPEUTIC MIGRAINE PRODUCTS
• 4.2 RESTRAINTS
  • 4.2.1 VOLUNTARY PRODUCT RECALL BY MARKET PLAYERS
• 4.3 OPPORTUNITY
  • 4.3.1 ONGOING CLINICAL TRIALS ASSOCIATED WITH MIGRAINE EFFICACY AND SAFETY
• 4.4 PORTER'S FIVE FORCES MODEL
  • 4.4.1 THREAT OF NEW ENTRANTS
  • 4.4.2 BARGAINING POWER OF SUPPLIERS
  • 4.4.3 THREAT OF SUBSTITUTES
  • 4.4.4 BARGAINING POWER OF BUYERS
  • 4.4.5 INTENSITY OF RIVALRY
• 4.5 IMPACT OF COVID-19 ON GLOBAL MIGRAINE MARKET

5 GLOBAL MIGRAINE MARKET, BY MIGRAINE TYPE

• 5.1 OVERVIEW
• 5.2 MIGRAINE WITH AURA
• 5.3 MIGRAINE WITHOUT AURA
• 5.4 OTHERS

6 GLOBAL MIGRAINE MARKET, BY TREATMENT

• 6.1 OVERVIEW
• 6.2 MEDICATION
  • 6.2.1 CGRP INHIBITORS
    • 6.2.1.1 RIMEGEPANT
    • 6.2.1.2 UBROGEPANT
    • 6.2.1.3 OTHERS
  • 6.2.2 TRIPTANS
    • 6.2.2.1 SUMATRIPTAN SUCCINATE
    • 6.2.2.2 ZOLMITRIPTAN
    • 6.2.2.3 RIZATRIPTAN
    • 6.2.2.4 OTHERS
  • 6.2.3 ERGOTS
    • 6.2.3.1 DIHYDROERGOTAMINE
    • 6.2.3.2 ERGOTAMINE TARTRATE
    • 6.2.3.3 OTHERS
  • 6.2.4 ACETYLCHOLINE INHIBITORS/ NEUROTOXINS
  • 6.2.5 NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS)
  • 6.2.6 BETA-BLOCKERS
  • 6.2.7 CALCIUM CHANNEL BLOCKERS
  • 6.2.8 DITANS
  • 6.2.9 OTHERS
• 6.3 DEVICE-BASED THERAPIES
  • 6.3.1 ELECTRICAL NEUROMODULATION DEVICE
  • 6.3.2 TRANSCRANIAL MAGNETIC STIMULATION DEVICE
  • 6.3.3 VAGUS NERVE STIMULATION DEVICE
  • 6.3.4 OTHERS

7 GLOBAL MIGRAINE MARKET, BY DISTRIBUTION CHANNEL

• 7.1 OVERVIEW
• 7.2 ONLINE
• 7.3 OFFLINE

8 GLOBAL MIGRAINE MARKET, BY REGION

• 8.1 OVERVIEW
• 8.2 NORTH AMERICA
  • 8.2.1 US
  • 8.2.2 CANADA
• 8.3 EUROPE
  • 8.3.1 GERMANY
  • 8.3.2 FRANCE
  • 8.3.3 UK
  • 8.3.4 ITALY
  • 8.3.5 SPAIN
  • 8.3.6 REST OF EUROPE
• 8.4 ASIA-PACIFIC
  • 8.4.1 CHINA
  • 8.4.2 INDIA
  • 8.4.3 JAPAN
  • 8.4.4 SOUTH KOREA
  • 8.4.5 AUSTRALIA
  • 8.4.6 NEW ZEALAND
  • 8.4.7 REST OF ASIA-PACIFIC
• 8.5 REST OF THE WORLD
  • 8.5.1 MIDDLE EAST
  • 8.5.2 LATIN AMERICA
  • 8.5.3 AFRICA

9 COMPETITIVE LANDSCAPE

• 9.1 INTRODUCTION
• 9.2 MARKET SHARE ANALYSIS, 2023
• 9.3 COMPETITOR DASHBOARD
• 9.4 PUBLIC PLAYERS STOCK SUMMARY
• 9.5 COMPARATIVE ANALYSIS: KEY PLAYERS FINANCIAL
• 9.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
  • 9.6.1 PRODUCT LAUNCH
  • 9.6.2 AGREEMENT
  • 9.6.3 PRODUCT APPROVAL
  • 9.6.4 COLLABORATION
  • 9.6.5 PRODUCT EXPANSION

10 COMPANY PROFILES

• 10.1 AMGEN INC
  • 10.1.1 COMPANY OVERVIEW
  • 10.1.2 FINANCIAL OVERVIEW
  • 10.1.3 PRODUCTS OFFERED
  • 10.1.4 KEY DEVELOPMENTS
  • 10.1.5 SWOT ANALYSIS
  • 10.1.6 KEY STRATEGIES
• 10.2 ELI LILLY AND COMPANY
  • 10.2.1 COMPANY OVERVIEW
  • 10.2.2 FINANCIAL OVERVIEW
  • 10.2.3 PRODUCTS OFFERED
  • 10.2.4 KEY DEVELOPMENTS
  • 10.2.5 SWOT ANALYSIS
  • 10.2.6 KEY STRATEGIES
• 10.3 ABBVIE INC.
  • 10.3.1 COMPANY OVERVIEW
  • 10.3.2 FINANCIAL OVERVIEW
  • 10.3.3 PRODUCTS OFFERED
  • 10.3.4 KEY DEVELOPMENTS
  • 10.3.5 KEY STRATEGIES
• 10.4 BAUSCH HEALTH COMPANIES INC.
  • 10.4.1 COMPANY OVERVIEW
  • 10.4.2 FINANCIAL OVERVIEW
  • 10.4.3 PRODUCTS OFFERED
  • 10.4.4 KEY DEVELOPMENTS
  • 10.4.5 KEY STRATEGIES
• 10.5 GSK PLC
  • 10.5.1 COMPANY OVERVIEW
  • 10.5.2 FINANCIAL OVERVIEW
  • 10.5.3 PRODUCT OFFERED
  • 10.5.4 KEY DEVELOPMENTS
  • 10.5.5 SWOT ANALYSIS
  • 10.5.6 KEY STRATEGIES
• 10.6 TEVA PHARMACEUTICAL INDUSTRIES LTD.
  • 10.6.1 COMPANY OVERVIEW
  • 10.6.2 FINANCIAL OVERVIEW
  • 10.6.3 PRODUCTS OFFERED
  • 10.6.4 KEY DEVELOPMENTS
  • 10.6.5 SWOT ANALYSIS
  • 10.6.6 KEY STRATEGIES
• 10.7 PFIZER INC.
  • 10.7.1 COMPANY OVERVIEW
  • 10.7.2 FINANCIAL OVERVIEW
  • 10.7.3 PRODUCTS OFFERED
  • 10.7.4 KEY DEVELOPMENTS
  • 10.7.5 KEY STRATEGIES
• 10.8 THERANICA BIO-ELECTRONICS LTD
  • 10.8.1 COMPANY OVERVIEW
  • 10.8.2 FINANCIAL OVERVIEW
  • 10.8.3 PRODUCTS OFFERED
  • 10.8.4 KEY DEVELOPMENTS
  • 10.8.5 KEY STRATEGIES
• 10.9 CEFALY
  • 10.9.1 COMPANY OVERVIEW
  • 10.9.2 FINANCIAL OVERVIEW
  • 10.9.3 PRODUCTS OFFERED
  • 10.9.4 KEY DEVELOPMENTS
  • 10.9.5 KEY STRATEGIES
• 10.10 ASTRAZENECA
  • 10.10.1 COMPANY OVERVIEW
  • 10.10.2 FINANCIAL OVERVIEW
  • 10.10.3 PRODUCTS OFFERED
  • 10.10.4 KEY DEVELOPMENTS
  • 10.10.5 SWOT ANALYSIS
  • 10.10.6 KEY STRATEGIES
• 10.11 DATA CITATIONS